Literature DB >> 18559293

LRP1 modulates APP trafficking along early compartments of the secretory pathway.

Elaine Waldron1, Catherine Heilig, Andrea Schweitzer, Nirupa Nadella, Sebastian Jaeger, Anne M Martin, Sascha Weggen, Klaudia Brix, Claus U Pietrzik.   

Abstract

The amyloid beta peptide (A beta) is a central player in Alzheimer's disease (AD) pathology. A beta liberation depends on APP cleavage by beta- and gamma-secretases. The low density lipoprotein receptor related protein 1 (LRP1) was shown to mediate APP processing at multiple steps. Newly synthesized LRP1 can interact with APP, implying an interaction between these two proteins early in the secretory pathway. We wanted to investigate whether LRP1 mediates APP trafficking along the secretory pathway, and, if so, whether it affects APP processing. Indeed, the early trafficking of APP within the secretory pathway is strongly influenced by its interaction with the C-terminal domain of LRP1. The LRP1-construct expressing an ER-retention motif, LRP-CT KKAA, had the capacity to retard APP traffic to early secretory compartments. In addition, we provide evidence that APP metabolism occurs in close conjunction with LRP1 trafficking, highlighting a new role of lipoprotein receptors in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559293     DOI: 10.1016/j.nbd.2008.04.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  38 in total

Review 1.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein.

Authors:  Sylvia Ullrich; Anna Münch; Stephanie Neumann; Elisabeth Kremmer; Jörg Tatzelt; Stefan F Lichtenthaler
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

3.  Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain.

Authors:  Joshua B Owen; Rukhsana Sultana; Christopher D Aluise; Michelle A Erickson; Tulin O Price; Guojun Bu; William A Banks; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2010-10-07       Impact factor: 7.376

4.  Low-Density Lipoprotein Receptor-Related Protein-1 (LRP1) C4408R Mutant Promotes Amyloid Precursor Protein (APP) α-Cleavage in Vitro.

Authors:  Huayan Hou; Ahsan Habib; Dan Zi; Kathy Tian; Jun Tian; Brian Giunta; Darrell Sawmiller; Jun Tan
Journal:  Neuromolecular Med       Date:  2017-06-13       Impact factor: 3.843

Review 5.  Insulin in the brain: there and back again.

Authors:  William A Banks; Joshua B Owen; Michelle A Erickson
Journal:  Pharmacol Ther       Date:  2012-07-17       Impact factor: 12.310

Review 6.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

Review 7.  The role of lipoprotein receptors on the physiological function of APP.

Authors:  Timo Wagner; Claus U Pietrzik
Journal:  Exp Brain Res       Date:  2011-09-23       Impact factor: 1.972

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.

Authors:  Mahmoud L Soliman; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-15       Impact factor: 4.147

Review 10.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.